CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA

CS96 209 SCH56592 与氟康唑治疗口咽念珠菌的比较

• 批准号: 6291146
• 负责人: JOSEPH WHEAT
• 金额: $ 0.04万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291146
• 关键词: HIV infections; antifungal agents; candidiasis; chemotherapy; clinical research; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation

This study will be carried out to assess safety, tolerability, and efficacy parameters in HIV-positive patients with oropharyngeal candidiasis (OPC), and also to select a dose or doses prior to initiation of studies in patients with systemic fungal infections. The primary objective: Demonstration of the clinical efficacy of the highest dose of SCH 56592.

这项研究将评估HIV阳性口咽念珠菌病(OPC)患者的安全性、耐受性和疗效参数，并在系统性真菌感染患者开始研究之前选择一个或多个剂量。主要目标：证明最大剂量SCH 56592的临床疗效。